ClinicalTrials.Veeva

Menu

Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer

N

National Cancer Center (NCC)

Status

Completed

Conditions

Ovarian Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT01538498
NCCCTS-08-309

Details and patient eligibility

About

  • Primary objectives: To develop peritoneal carcinomatosis index (PCI) for ovarian cancer, tubal cancer and primary peritoneal cancer that can represent perioperative intraperitoneal tumor burden objectively
  • Secondary objectives: To establish the relationship and find out clinical significance between PCI, tumor location and tumor characteristics

Full description

Patients with primary ovarian cancer

  • Informed consent

  • Digital photography & Checking PCI (tumor size, number, and Characteristics)

  • Postoperative surveillance(tumor marker, image and physical examination)

    1. Developing the best fitting PCI model to reflect recurrence-free survival and overall survival

      • Selection of items
      • Weighting by items and tumor characteristics
    2. Analysis of prognostic impact of PCI compared to conventional staging system (FIGO stage) for ovarian cancer

Enrollment

134 patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Preoperative clinical diagnosis of ovarian cancer, tubal cancer, and primary peritoneal carcinoma (all stage)
  2. Available preoperative image study (CT and/or MRI and/or PET)
  3. Patients who gave a written informed consent
  4. Patients must be surgical candidate considering medical and psychological condition

Exclusion criteria

  • Patients who refuse to participate or want to withdraw at anytime.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems